Advanced Materials · 2025 · 30 citations · 38 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesTherapeutic VaccinationTumor AntigensVaccine PlatformsImmune Checkpoint LigandsImmunogenicity EnhancementNanovaccinesOuter Membrane Vesicle VaccinePd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayTumor Antigen VaccinesTumor Antigen-based Immunotherapy
Antigen-presenting cells (APCs) process tumor vaccines and present tumor antigens as the first signals to T cells to activate anti-tumor immunity, which process requires the assistance of co-stimulatory second signals on APCs. The immune checkpoint programmed death ligand 1 (PD-L1) not only mediates the immune escape of tumor cells but also acts as a co-inhibitory second signal on APCs. The serious dysfunction of second signals due to the high expression of PD-L1 on APCs in the tumor body results in the inefficiency of tumor vaccines. To overcome this challenge, a previously established Plug-and-Display tumor vaccine platform based on bacterial outer membrane vesicles (OMVs) is developed into an "Antigen Presentation Signal Enhancer" (APSE) by surface-modifying PD-L1 antibodies (αPD-L1). While delivering tumor antigens, APSE can activate the expression of co-stimulatory second signals in APCs due to the high immunogenicity of OMVs. More importantly, the surface-modified αPD-L1 binds to the co-inhibitory signals PD-L1, potentially restoring CD80 function and ensuring efficient co-stimulatory second signals and activation of anti-tumor immunity. The results reveal the importance of PD-L1 blockage in the initiation process of anti-tumor immunity, and the second signal modulation capability of APSE can expand the application potential of cancer vaccines to less immunogenic malignancies.
38
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng, Hua Liang, Byron Burnette et al. · Journal of Clinical Investigation · 2014 · 2.1K citations
Medicine, Immunology, Oncology +17
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
Tyler J. Curiel, Shuang Wei, Haidong Dong et al. · Nature Medicine · 2003 · 1.3K citations
Life Sciences, Immunology, Oncology +15
Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours
J. Justin Milner, Clara Toma, Bingfei Yu et al. · Nature · 2017 · 688 citations
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Soyoung Oh, Dai-Chen Wu, Jeanne Cheung et al. · Nature Cancer · 2020 · 459 citations
Life Sciences, Immunology, Oncology +17